LEADING RESEARCH INSTITUTES IN HARBIN ARE INTERESTED IN MICROSOURCES PRODUCED BY BEBIG"LLC FOR CANCER TREATMENT
In the framework of the second Russian-Chinese trade fair, which took place on October 12 - 15, in Harbin, BEBIG Company represented microsources for prostate cancer treatment by low-dose-rate brachytherapy. This method is considered to be the most efficient and less traumatic in treating the early stages of cancer.
Russian microsources of BEBIG Company and the possibilities of low-dose-rate brachytherapy in the treatment of prostate cancer were presented to the Governor of Heilongjiang Province Lu Hao, as well as a number of the leading scientific organizations of the province, including: the Academy of Social Sciences of Heilongjiang Province, Harbin Institute of Technology, Harbin Medical University, Biological Scientific Research Institute of Jilin, the Administrative Committee of the Harbin area of technical and economic development. The parties planned a program of activities aimed at the implementation of the low-dose-rate brachytherapy into the practice of medical institutions, Heilongjiang Province, including exchange of accumulated experience between Russian and Chinese oncourologists.
"We supply our products to the leading clinics of Russia, Armenia and Kazakhstan. I have no doubt that high production capacities of our plant will partially meet the needs of medical institutions and other countries, including China, the market of which we are now analyzing and working on options for mutually beneficial cooperation", - says Kirill Mayorov, Director General of BEBIG LLC. Prostate cancer is currently ranked 1st - 2nd place in the structure of morbidity and 2nd - 3rd place in the structure of mortality from cancer diseases among men in most developed countries. According to GLOBOCAN 2012, IARC (International Agency for Research on Cancer) more than 47 000 cases of prostate cancer have been registered in China. Modern methods of prostate cancer treatment, such as low-dose-rate brachytherapy, allow conducting effective medical treatment for this disease.